Coston McIsaac & Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Coston McIsaac & Partners’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-14	Closed	-$5K	–	919
2025 Q3	$5K	Hold	14	–	–	﹤0.01%	633
2025 Q2	$6K	Hold	14	–	–	﹤0.01%	598
2025 Q1	$6K	Hold	14	–	–	﹤0.01%	577
2024 Q4	$5K	Hold	14	–	–	﹤0.01%	591
2024 Q3	$6	Hold	14	–	–	﹤0.01%	583
2024 Q2	$6K	Hold	14	–	–	﹤0.01%	549
2024 Q1	$5K	Hold	14	–	–	﹤0.01%	579
2023 Q4	$5K	Hold	14	–	–	﹤0.01%	573
2023 Q3	$4K	Hold	14	–	–	﹤0.01%	593
2023 Q2	$4K	Sell	14 -7	-33%	-$2.36K	﹤0.01%	638
2023 Q1	$6K	Buy	21 +7	+50%	+$2.1K	﹤0.01%	570
2022 Q4	$4	Hold	14	–	–	﹤0.01%	629
2022 Q3	$4K	Hold	14	–	–	﹤0.01%	541
2022 Q2	$4K	Buy	+14	New	+$3.75K	﹤0.01%	379

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Coston McIsaac & Partners's VRTX Position: Q4 2025 in Review

Coston McIsaac & Partners sold out of Vertex Pharmaceuticals (VRTX) in Q4 2025, closing a stake of 14 shares — an estimated $5K sold.

Coston McIsaac & Partners first reported a position in VRTX in Q2 2022 and held it in 14 quarters. The position peaked at $6K in Q2 2025. 1,669 funds tracked by Wall St. Rank hold VRTX as of Q4 2025.

Coston McIsaac & Partners reported no remaining Vertex Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Coston McIsaac & Partners sold 14 Vertex Pharmaceuticals shares in Q4 2025, an estimated $5K.
Coston McIsaac & Partners first reported a position in Vertex Pharmaceuticals in Q2 2022 and held it in 14 quarters.
Coston McIsaac & Partners's Vertex Pharmaceuticals position peaked at $6K in Q2 2025.
1,669 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2025.

Based on Coston McIsaac & Partners's 13F filing for Q4 2025, filed 3 Feb 2026.